• +1-646-491-9876
    • +91-20-67278686

    Search

    Thromboembolism-Pipeline Review H2 2017

    Thromboembolism-Pipeline Review H2 2017

    • Report Code ID: RW0001881463
    • Category Life Sciences
    • No. of Pages 95
    • Publication Month Jul-17
    • Publisher Name Global Markets Direct
    Thromboembolism-Pipeline Review H2 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Thromboembolism-Pipeline Review H2 2017 provides an overview of the Thromboembolism (Cardiovascular) pipeline landscape.

    When a blood clot (thrombus) breaks and travels in the blood this is called a thromboembolism. Symptoms include warmth edema and erythema and may also include dilated veins (collaterals) on the chest wall or leg. Risk factors include hypertension diabetes mellitus cigarette smoking and high cholesterol levels. Treatment includes anticoagulants thrombolytic therapy and surgery.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Thromboembolism-Pipeline Review H2 2017 provides comprehensive information on the therapeutics under development for Thromboembolism (Cardiovascular) complete with analysis by stage of development drug target mechanism of action (MoA) route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics its complete research and development history and latest news and press releases.

    The Thromboembolism (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Thromboembolism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes the molecules developed by Companies in Pre-Registration Phase II Phase I IND/CTA Filed and Preclinical stages are 4 2 1 1 and 4 respectively. Similarly the Universities portfolio in Preclinical stages comprises 4 molecules respectively.

    Thromboembolism (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases company/university websites clinical trial registries conferences SEC filings investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Thromboembolism (Cardiovascular) .
    - The pipeline guide reviews pipeline therapeutics for Thromboembolism (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise product description descriptive licensing and collaboration details R&D brief MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Thromboembolism (Cardiovascular) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Thromboembolism (Cardiovascular) therapeutics based on mechanism of action (MoA) drug target route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Thromboembolism (Cardiovascular)

    Reasons to buy

    - Procure strategically important competitor information analysis and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Thromboembolism (Cardiovascular) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Thromboembolism (Cardiovascular) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Thromboembolism-Overview
    Thromboembolism-Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Thromboembolism-Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Thromboembolism-Companies Involved in Therapeutics Development
    Bayer AG
    China Biologic Products Inc
    Daiichi Sankyo Company Ltd
    F. Hoffmann-La Roche Ltd
    Gamma Therapeutics Inc
    GlycoMimetics Inc
    Green Cross Corp
    Ionis Pharmaceuticals Inc
    Portola Pharmaceuticals Inc
    Verseon Corp
    Thromboembolism-Drug Profiles
    antithrombin III (human)-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    betrixaban-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    C-3-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    edoxaban tosylate-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Gammarin-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GCC-2107-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GMI-1271-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    IONIS-FXIRx-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Lysimab-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Peptide to Inhibit PAI-1 for Arterial Thrombosis and Pulmonary Thromboembolism-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Recombinant Protein for Thromboembolism-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    rivaroxaban-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit Thrombin for Cardiovascular Diseases-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TAP-ANV-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TRX-1-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    YG-001-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Thromboembolism-Dormant Projects
    Thromboembolism-Discontinued Products
    Thromboembolism-Product Development Milestones
    Featured News & Press Releases
    Jun 28 2017 U.S. FDA Grants Priority Review of XARELTO (rivaroxaban) sNDA for a 10 mg Dose to Reduce the Risk of Recurrent Venous Thromboembolism
    Jun 23 2017 FDA approved betrixaban (BEVYXXA Portola) for the prophylaxis of venous thromboembolism (VTE) in adult patients
    Apr 28 2017 Rivaroxaban 10 mg Once Daily from Bayer Submitted to U.S. FDA as Additional Dose Option to Reduce the Risk of Recurrent Venous Thromboembolism
    Mar 18 2017 Bayer's Rivaroxaban Demonstrated Superior Protection Against Recurrent Venous Thromboembolism Compared with Aspirin in EINSTEIN CHOICE Study
    Mar 13 2017 Daiichi Sankyo Announces Large-scale Registry of Venous Thromboembolism in Cancer Patients
    Mar 07 2017 Portola Pharmaceuticals Announces Betrixaban Presentations at ACC.17
    Mar 06 2017 EINSTEIN CHOICE Study with Bayer's Rivaroxaban Accepted for Late-Breaking Clinical Trial Presentation at ACC.17
    Feb 08 2017 FDA Informs Portola Pharmaceuticals at Mid-Cycle Review for Betrixaban That It Has Not Identified Issues that Require an Advisory Committee Meeting
    Dec 23 2016 Portola Pharmaceuticals Announces FDA Accepts New Drug Application for Priority Review and EMA Validates Marketing Authorization Application for Oral Factor Xa Inhibitor Anticoagulant Betrixaban
    Dec 08 2016 Daiichi Sankyo Announces Initiation of Real-World Study in LIXIANA (edoxaban) Patients Undergoing Diagnostic and Therapeutic Procedures in NVAF and VTE
    Dec 06 2016 New Analysis Shows People with Cancer Who Received XARELTO (rivaroxaban) for Blood Clots Had Fewer ER Visits and Lower Healthcare Costs than Those Given Standard Treatment
    Dec 06 2016 ASH 2016 Explaining the lower bleeding risk of Verseon's anticoagulants
    Nov 28 2016 Portola Pharmaceuticals Announces Betrixaban Data to be Presented at 2016 American Society of Hematology Annual Meeting and Exposition
    Nov 28 2016 Ten Abstracts on the Use of Bayer's Xarelto in Different Patient Populations Accepted for Presentation at ASH 2016
    Nov 28 2016 Research to Be Presented at ASH Annual Meeting Shows Verseon's New Class of Anticoagulants Prevents Thrombosis While Preserving Platelet Function
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Thromboembolism H2 2017
    Number of Products under Development by Companies H2 2017
    Number of Products under Development by Universities/Institutes H2 2017
    Products under Development by Companies H2 2017
    Products under Development by Universities/Institutes H2 2017
    Number of Products by Stage and Target H2 2017
    Number of Products by Stage and Mechanism of Action H2 2017
    Number of Products by Stage and Route of Administration H2 2017
    Number of Products by Stage and Molecule Type H2 2017
    Thromboembolism-Pipeline by Bayer AG H2 2017
    Thromboembolism-Pipeline by China Biologic Products Inc H2 2017
    Thromboembolism-Pipeline by Daiichi Sankyo Company Ltd H2 2017
    Thromboembolism-Pipeline by F. Hoffmann-La Roche Ltd H2 2017
    Thromboembolism-Pipeline by Gamma Therapeutics Inc H2 2017
    Thromboembolism-Pipeline by GlycoMimetics Inc H2 2017
    Thromboembolism-Pipeline by Green Cross Corp H2 2017
    Thromboembolism-Pipeline by Ionis Pharmaceuticals Inc H2 2017
    Thromboembolism-Pipeline by Portola Pharmaceuticals Inc H2 2017
    Thromboembolism-Pipeline by Verseon Corp H2 2017
    Thromboembolism-Dormant Projects H2 2017
    Thromboembolism-Discontinued Products H2 2017

    List of Figures

    Number of Products under Development for Thromboembolism H2 2017
    Number of Products under Development by Companies H2 2017
    Number of Products by Targets H2 2017
    Number of Products by Stage and Targets H2 2017
    Number of Products by Mechanism of Actions H2 2017
    Number of Products by Stage and Mechanism of Actions H2 2017
    Number of Products by Routes of Administration H2 2017
    Number of Products by Stage and Routes of Administration H2 2017
    Number of Products by Molecule Types H2 2017
    Number of Products by Stage and Molecule Types H2 2017
    Bayer AG
    China Biologic Products Inc
    Daiichi Sankyo Company Ltd
    F. Hoffmann-La Roche Ltd
    Gamma Therapeutics Inc
    GlycoMimetics Inc
    Green Cross Corp
    Ionis Pharmaceuticals Inc
    Portola Pharmaceuticals Inc
    Verseon Corp

    Request for Sample

    Report Url http://www.reportsweb.com//thromboembolism-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//thromboembolism-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//thromboembolism-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments